Eiger BioPharmaceuticals, Inc.
EIGRDelisted Apr 25, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001305253
Eiger BioPharmaceuticals, Inc. was delisted on Apr 25, 2024; its insiders filed their last Form 4 on Nov 2, 2023; 43 institutions reported holding it in 13F filings for Q4 2023, worth $4.16M in total; no superinvestor held it.
13F holders, Q1 2025
Institutional positions in Eiger BioPharmaceuticals, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
EIGR is no longer listed, and 13F filings after Q4 2023 list far fewer holders. See Q4 2023
- Institutional holders
- 1
- 0 vs. Q4 2024
- Shares held
- 146.4K
- 0 (0.0%) vs. Q4 2024
- Total value
- $423.0K
- −$342.0K (−44.7%) vs. Q4 2024
- New holders
- 0
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EIGR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 1 | $423.0K |
| Q1 2025 | 1 | $423.0K |
| Q4 2024 | 1 | $765.0K |
| Q3 2024 | 1 | $1.24M |
| Q2 2024 | 2 | $1.85M |
| Q1 2024 | 24 | $3.19M |
| Q4 2023 | 43 | $4.16M |
| Q3 2023 | 51 | $6.08M |
| Q2 2023 | 67 | $14.6M |
| Q1 2023 | 71 | $22.2M |
| Q4 2022 | 81 | $29.6M |
| Q3 2022 | 92 | $225.3M |
| Q2 2022 | 91 | $187.8M |
| Q1 2022 | 95 | $252.0M |
| Q4 2021 | 86 | $124.1M |
| Q3 2021 | 92 | $151.0M |
| Q2 2021 | 90 | $196.3M |
| Q1 2021 | 94 | $207.5M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Eiger BioPharmaceuticals, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Propel Bio Management, LLC | 146,381 | $423.0K | 0.49% | 00.0% | Unchanged |